Pirtobrutinib With Sonrotoclax and Rituximab for High-Risk Relapsed/Refractory Mantle-Cell Lymphoma Following Covalent BTK-Inhibitor Failure
Mantle Cell Lymphoma (MCL); Relapsed/Refractory Mantle Cell Lymphoma (MCL)
source: ClinicalTrials.govlicence: US NLM public datadatabase: /home/dbs/health.dbmode: tablerecords: 612567 (max_rowid)citation: https://clinicaltrials.gov/
Mantle Cell Lymphoma (MCL); Relapsed/Refractory Mantle Cell Lymphoma (MCL)
Fields
| status | NOT_YET_RECRUITING |
|---|---|
| phase | ['PHASE2'] |
| study_type | INTERVENTIONAL |
| countries | China |
| sponsor | Tianjin Medical University Cancer Institute and Hospital |
| start_date | 2026-12-08 |
| completion_date | 2030-12-08 |
source: ClinicalTrials.govlicence: US NLM public datayear: —id: NCT07944651citation: https://clinicaltrials.gov/study/NCT07944651